✦ LIBER ✦

A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis

✍ Scribed by Stein, M. S.; Liu, Y.; Gray, O. M.; Baker, J. E.; Kolbe, S. C.; Ditchfield, M. R.; Egan, G. F.; Mitchell, P. J.; Harrison, L. C.; Butzkueven, H.; Kilpatrick, T. J.

Book ID: 118153904
Publisher: Lippincott Williams and Wilkins
Year: 2011
Tongue: English
Weight: 634 KB
Volume: 77
Category: Article
ISSN: 0028-3878
DOI: 10.1212/wnl.0b013e3182343274

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

INTRAVENOUS IMMUNOGLOBULIN IN RELAPSING-

INTRAVENOUS IMMUNOGLOBULIN IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: A DOSE-FINDING TRIAL

✍ Khan, O. A.; Tselis, A.; Boster, A.; Fazekas, F.; Lublin, F.D.; Li, D.; Freedman 📂 Article 📅 2009 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 149 KB

INTRAVENOUS IMMUNOGLOBULIN IN RELAPSING-

INTRAVENOUS IMMUNOGLOBULIN IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: A DOSE-FINDING TRIAL

✍ Engel, W. K.; Fazekas, F.; Lublin, F.D.; Li, D.; Freedman, M.S.; Hartung, H.P.; 📂 Article 📅 2009 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 128 KB

Intravenous immunoglobulin treatment in

Intravenous immunoglobulin treatment in relapsing-remitting multiple sclerosis: A randomized, double-blind multicenter, placebo-controlled trial

✍ A. Achiron; R. Gilad; S. Hassin; Y. Barak; U. Gabbay; I. Ziv; Y. Goldhamer; E. M 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 144 KB

Ocrelizumab in relapsing-remitting multi

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

✍ Ludwig Kappos; David Li; Peter A Calabresi; Paul O'Connor; Amit Bar-Or; Frederik 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 337 KB

Ocrelizumab in relapsing-remitting multi

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

✍ Ludwig Kappos; David Li; Peter A Calabresi; Paul O'Connor; Amit Bar-Or; Frederik 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 337 KB

## Background: B lymphocytes are implicated in the pathogenesis of multiple sclerosis. we aimed to assess efficacy and safety of two dose regimens of the humanised anti-cd20 monoclonal antibody ocrelizumab in patients with relapsing-remitting multiple sclerosis. ## Methods: We did a multicentre,

Open controlled therapeutic trial of int

Open controlled therapeutic trial of intravenous immunoglobulins in relapsing-remitting multiple sclerosis

✍ A. Achiron; E. Pras; R. Gilad; C.R. Gordon; I. Ziv; I. Sarova-Pinhas; E. Melamed 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 68 KB